Astellas' investigational non-hormonal treatment demonstrates reduction in frequency and severity of moderate to severe vasomotor symptoms (VMS) associated with menopause TOKYO, Sept. 22, 2021 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback